APA (7th ed.) Citation

U, M., J, T., S, N., T, N., AM, L., S, H., . . . KM, K. (2026). Loss of GPRC5D enhances the proliferative capacity and competitive fitness of myeloma upon anti-GPRC5D immunotherapy. Leukemia, 40(6), 1227. https://doi.org/10.1038/s41375-026-02920-7

Chicago Style (17th ed.) Citation

U, Munawar, et al. "Loss of GPRC5D Enhances the Proliferative Capacity and Competitive Fitness of Myeloma upon Anti-GPRC5D Immunotherapy." Leukemia 40, no. 6 (2026): 1227. https://doi.org/10.1038/s41375-026-02920-7.

MLA (9th ed.) Citation

U, Munawar, et al. "Loss of GPRC5D Enhances the Proliferative Capacity and Competitive Fitness of Myeloma upon Anti-GPRC5D Immunotherapy." Leukemia, vol. 40, no. 6, 2026, p. 1227, https://doi.org/10.1038/s41375-026-02920-7.